Michael Saylor is apparently done thinking small. The founder and CEO of MicroStrategy announced Wednesday that his company ...
Biotech stock Halozyme Therapeutics is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback